^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Acute Myelogenous Leukemia
    Drug:Daurismo (glasdegib) (Hedgehog cell-signalling pathway inhibitor, SMO protein inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    06/26/2020
    Excerpt:
    Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
    Secondary therapy:
    cytarabine
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    11/21/2018
    Excerpt:
    DAURISMO is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
    Secondary therapy:
    cytarabine
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    For AML patients declining intensive remission induction therapy...regimens include venetoclax combined with chemotherapy...or glasdegib combined with LDAC.
    Secondary therapy:
    cytarabine